Patient Characteristics and Treatment Patterns with Macitentan in Pulmonary Arterial Hypertension: Insights from the OPUS Registry

被引：0
|
作者：
Channick, R. [1 ]
Chin, K. [2 ]
Kim, N. [3 ]
Brand, M. [4 ]
Morganti, A. [4 ]
Selej, M. [5 ]
McLaughlin, V. [6 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[3] Univ Calif San Diego, La Jolla, CA 92093 USA
[4] Actel Pharmaceut Ltd, Allschwil, Switzerland
[5] Actel Pharmaceut US Inc, San Francisco, CA USA
[6] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2019年 / 38卷 / 04期
关键词：
D O I：
10.1016/j.healun.2019.01.1245
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1235
引用
收藏
页码：S489 / S490
页数：2
相关论文
共 50 条
  • [1] Opus Registry: Treatment Patterns With Macitentan In Patients With Pulmonary Arterial Hypertension
    Chin, K.
    Channick, R. N.
    Kim, N. H.
    Muros-Le Rouzic, E.
    Selej, M.
    McLaughlin, V.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [2] Patient Characteristics and Treatment Patterns in the Largest Real-World Cohort of Pulmonary Arterial Hypertension Patients Newly Treated with Macitentan: OPsumit® USers (OPUS) Registry
    Channick, R. N.
    Chin, K. M.
    Kim, N. H.
    Melendres-Groves, L.
    Rouzic, E. Muros-Le
    Selej, M.
    McLaughlin, V. V.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [3] OPUS Registry: Treatment Patterns and Safety of Macitentan in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (PAH-SSc)
    Chin, Kelly
    Kim, Nick
    Channick, Richard
    Rouzic, Erwan Muros-Le
    Selej, Mona
    McLaughlin, Vallerie
    [J]. CHEST, 2017, 152 (04) : 999A - 1000A
  • [4] Macitentan in chronic thromboembolic pulmonary hypertension (CTEPH): experience from the OPUS registry
    Kim, Nick
    Channick, Richard
    Mclaughlin, Vallerie
    Mcconnell, John
    Poch, David
    Brand, Monika
    Muros-Le Rouzic, Erwan
    Selej, Mona
    Chin, Kelly
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [5] CHARACTERIZING PATIENTS TREATED WITH MACITENTAN FOR PULMONARY ARTERIAL HYPERTENSION (PAH) IN THE US OPSUMIT USERS REGISTRY (OPUS)
    McLaughlin, V. V.
    Channick, R. M.
    Lickert, C.
    Pruett, J.
    Selej, M.
    Drake, W.
    [J]. VALUE IN HEALTH, 2018, 21 : S55 - S55
  • [6] MACITENTAN FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
    Spikes, L.
    Williamson, T.
    Satterwhite, L.
    [J]. DRUGS OF TODAY, 2014, 50 (06) : 401 - 406
  • [7] Macitentan for the treatment of pulmonary arterial hypertension
    Kholdani, Cyrus A.
    Fares, Wassim H.
    Trow, Terence K.
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2014, 10 : 665 - 673
  • [8] Macitentan - treatment of pulmonary arterial hypertension
    Campean, I. -A.
    Sadushi-Kolici, R.
    Skoro-Sajer, N.
    Panzenboeck, A.
    Lang, I.
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 : S250 - S251
  • [9] Macitentan for the Treatment of Pulmonary Arterial Hypertension
    Hong, Irene S.
    Coe, Holly V.
    Catanzaro, Linda M.
    [J]. ANNALS OF PHARMACOTHERAPY, 2014, 48 (04) : 538 - 547
  • [10] Macitentan for the treatment of pulmonary arterial hypertension
    DuBrock, Hilary M.
    Channick, Richard N.
    [J]. EXPERT REVIEW OF RESPIRATORY MEDICINE, 2014, 8 (04) : 393 - 399
12345